Control of baseline cardiovascular risk factors in the SU-FOL-OM3 study cohort: does the localization of the arterial event matter?
- PMID: 20216318
- DOI: 10.1097/HJR.0b013e3283383f47
Control of baseline cardiovascular risk factors in the SU-FOL-OM3 study cohort: does the localization of the arterial event matter?
Abstract
Aim and method: No data are currently available on the prevalence and control of cardiovascular (CV) risk factors in secondary prevention depending on the cardiac or cerebral localization of the ischemic disease. We investigated the prevalence and control of modifiable CV risk factors, as well as the determinants of CV risk factors' control and adequate treatment in a secondary prevention cohort, the SU-FOL-OM3 study cohort, to determine the role of the localization of the ischemic disease including events.
Results: A total of 2491 patients were included in the study. The prevalence of all modifiable risk factors was high in both coronary heart disease and cerebrovascular disease (CVD) groups. Control of all risk factors and the presence of antiplatelet medication were noted in 29.6% of patients with coronary heart disease and 11% of patients with CVD. The cardiac localization of the including event was independently associated with the control of each of the risk factors studied (hypertension, low-density lipoprotein-cholesterol, smoking) and to the control of all risk factors present and prescription of antiplatelet therapy with an odds ratio (95% confidence interval) of 2.72 (1.97-3.75).
Conclusion: There is a need to improve the control of CV risk factors in secondary prevention patients. This is particularly crucial for patients with CVD.
Comment in
-
Prevention: Supplements not cardioprotective for patients with a history of CVD.Nat Rev Cardiol. 2011 Feb;8(2):63. doi: 10.1038/nrcardio.2010.215. Nat Rev Cardiol. 2011. PMID: 21348141 No abstract available.
Similar articles
-
B vitamin and/or ω-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial.Arch Intern Med. 2012 Apr 9;172(7):540-7. doi: 10.1001/archinternmed.2011.1450. Epub 2012 Feb 13. Arch Intern Med. 2012. PMID: 22331983 Clinical Trial.
-
Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries.J Nutr Health Aging. 2003;7(6):428-35. J Nutr Health Aging. 2003. PMID: 14625623 Clinical Trial.
-
Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):556-61. doi: 10.1097/HJR.0b013e328338978e. Eur J Cardiovasc Prev Rehabil. 2010. PMID: 20305563
-
[Secondary prevention of arteriosclerosis].Praxis (Bern 1994). 1996 Sep 24;85(39):1201-5. Praxis (Bern 1994). 1996. PMID: 8927904 Review. German.
-
Cardiovascular protection paradigms: is change on the horizon?Rev Cardiovasc Med. 2007 Fall;8(4):200-13. Rev Cardiovasc Med. 2007. PMID: 18192943 Review.
Cited by
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Nov 30;11(11):CD003177. doi: 10.1002/14651858.CD003177.pub4. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2020 Feb 29;3:CD003177. doi: 10.1002/14651858.CD003177.pub5. PMID: 30521670 Free PMC article. Updated.
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD003177. doi: 10.1002/14651858.CD003177.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2018 Nov 30;11:CD003177. doi: 10.1002/14651858.CD003177.pub4. PMID: 30019766 Free PMC article. Updated.
-
Marine-derived n-3 fatty acids therapy for stroke.Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD012815. doi: 10.1002/14651858.CD012815.pub3. Cochrane Database Syst Rev. 2022. PMID: 35766825 Free PMC article.
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2020 Feb 29;3(3):CD003177. doi: 10.1002/14651858.CD003177.pub5. Cochrane Database Syst Rev. 2020. PMID: 32114706 Free PMC article.
-
Homocysteine-lowering interventions for preventing cardiovascular events.Cochrane Database Syst Rev. 2017 Aug 17;8(8):CD006612. doi: 10.1002/14651858.CD006612.pub5. Cochrane Database Syst Rev. 2017. PMID: 28816346 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical